Re:
|
Vanda Pharmaceuticals Inc. | |
Registration Statement on Form S-1 (File No. 333-116384) |
| should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; | ||
| the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and | ||
| the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Very truly yours, Vanda Pharmaceuticals Inc. |
||||
By: | /s/ Mihael H. Polymeropoulos, M.D. | |||
Mihael H. Polymeropoulos, M.D. | ||||
Chief Executive Officer | ||||
cc: | Steven A. Shallcross, Vanda Pharmaceuticals Inc. Jay K. Hachigian, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Gregg A. Griner, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Steven L. Baglio, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Richard Truesdell, Davis Polk & Wardwell Jeffrey Pohlman, Davis Polk & Wardwell |